Press Release

Daewoong Pharmaceutical’s press release

NEW 1 Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics: 2025-0611

NEW 2 Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on ‘Bersiporocin’ at ATS 2025, Highlights Global Patient Demographics: 2025-0604

NEW 3 Daewoong Pharmaceutical Announces Financial Results for 2024: 2025-0210

Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development 2022-02-21
Daewoong Pharmaceutical Released Positive Phase 3 Topline Results for New Antidiabetic Drug 2022-01-25
Daewoong’s “Leaps and Bounds” Q3 Performance... Exceeds KRW 20B in Operating Income for Three Consecutive Quarters 2021-11-01
Daewoong Pharmaceutical and Hanall Biopharma Invest $1M USD in Alloplex Biotherapeutics 2021-08-19
Daewoong, Q1 is just early stage of better performance 2021-05-06
Daewoong Pharmaceutical Signs Agreement to Export Fexuprazan, A New Drug for Gastroesophageal Reflux Disease, to China 2021-03-18
Daewoong Pharmaceutical obtains authorization for manufacturing ATMPs... Entering the CDMO business 2021-01-14
Daewoong Pharmaceutical’s Olostar confirmed better effect than co-administration of individual drugs 2021-01-06
Daewoong Pharmaceutical’s gastroesophageal reflux disease drug Fexuprazan obtained approval for a phase-3 trial in China 2020-12-30

1 2 3 4 5 6 7 8 9 10 다음 페이지

Search